Virtual discovery of melatonin receptor ligands to modulate circadian rhythms

The neuromodulator melatonin synchronizes circadian rhythms and related physiological functions through the actions of two G-protein-coupled receptors: MT 1 and MT 2 . Circadian release of melatonin at night from the pineal gland activates melatonin receptors in the suprachiasmatic nucleus of the hypothalamus, synchronizing the physiology and behaviour of animals to the light–dark cycle 1 – 4 . The two receptors are established drug targets for aligning circadian phase to this cycle in disorders of sleep 5 , 6 and depression 1 – 4 , 7 – 9 . Despite their importance, few in vivo active MT 1 -selective ligands have been reported 2 , 8 , 10 – 12 , hampering both the understanding of circadian biology and the development of targeted therapeutics. Here we docked more than 150 million virtual molecules to an MT 1 crystal structure, prioritizing structural fit and chemical novelty. Of these compounds, 38 high-ranking molecules were synthesized and tested, revealing ligands with potencies ranging from 470 picomolar to 6 micromolar. Structure-based optimization led to two selective MT 1 inverse agonists—which were topologically unrelated to previously explored chemotypes—that acted as inverse agonists in a mouse model of circadian re-entrainment. Notably, we found that these MT 1 -selective inverse agonists advanced the phase of the mouse circadian clock by 1.3–1.5 h when given at subjective dusk, an agonist-like effect that was eliminated in MT 1 - but not in MT 2 -knockout mice. This study illustrates the opportunities for modulating melatonin receptor biology through MT 1 -selective ligands and for the discovery of previously undescribed, in vivo active chemotypes from structure-based screens of diverse, ultralarge libraries. A computational screen of an ultra-large virtual library against the structure of the melatonin receptor found nanomolar ligands, and ultimately two selective MT 1 inverse agonists that induced phase advancement of the mouse circadian clock when given at subjective dusk.

[1]  M. Dubocovich,et al.  Melatonin and Light Induce Phase Shifts of Circadian Activity Rhythms in the C3H/HeN Mouse , 1996, Journal of biological rhythms.

[2]  U. Singh,et al.  A NEW FORCE FIELD FOR MOLECULAR MECHANICAL SIMULATION OF NUCLEIC ACIDS AND PROTEINS , 1984 .

[3]  D. Zlotos,et al.  Novel difluoroacetamide analogues of agomelatine and melatonin: probing the melatonin receptors for MT1 selectivity , 2015 .

[4]  Brian K. Shoichet,et al.  Ligand Pose and Orientational Sampling in Molecular Docking , 2013, PloS one.

[5]  Joanna L. Sharman,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands , 2015, Nucleic Acids Res..

[6]  Hualiang Jiang,et al.  Structural insights into lipid and ligand regulation of serotonin receptors , 2019, Nature.

[7]  Reid H. J. Olsen,et al.  XFEL structures of the human MT2 melatonin receptor reveal basis of subtype selectivity , 2019, Nature.

[8]  Reid H. J. Olsen,et al.  Structural insights into lipid and ligand regulation of serotonin receptors , 2019, Nature.

[9]  M. Gillette,et al.  Signaling in the suprachiasmatic nucleus: selectively responsive and integrative , 2002, Cell and Tissue Research.

[10]  Brian K. Shoichet,et al.  Rapid Context-Dependent Ligand Desolvation in Molecular Docking , 2010, J. Chem. Inf. Model..

[11]  M. Dubocovich,et al.  Familial advanced sleep phase syndrome. , 2001, Archives of neurology.

[12]  R. Stevens,et al.  Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.

[13]  Maria F. Sassano,et al.  PRESTO-TANGO: an open-source resource for interrogation of the druggable human GPCR-ome , 2015, Nature Structural &Molecular Biology.

[14]  Jonathan S. Mason,et al.  Structures of G protein-coupled receptors reveal new opportunities for drug discovery. , 2015, Drug discovery today.

[15]  M. Dubocovich,et al.  Carbamate Insecticides Target Human Melatonin Receptors. , 2017, Chemical research in toxicology.

[16]  M. Dubocovich,et al.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors , 2010, Pharmacological Reviews.

[17]  M. Dubocovich,et al.  Update on melatonin receptors: IUPHAR Review 20 , 2016, British journal of pharmacology.

[18]  K. Sharp,et al.  Electrostatic contributions to heat capacity changes of DNA-ligand binding. , 1998, Biophysical journal.

[19]  Reid H. J. Olsen,et al.  XFEL crystal structure of human melatonin receptor MT2 (H208A) in complex with 2-phenylmelatonin , 2019 .

[20]  M. Dubocovich,et al.  Constitutively active melatonin MT(1) receptors in male rat caudal arteries. , 2002, European journal of pharmacology.

[21]  Terry Kenakin,et al.  Biased Receptor Signaling in Drug Discovery , 2019, Pharmacological Reviews.

[22]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[23]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[24]  Maria F. Sassano,et al.  Automated design of ligands to polypharmacological profiles , 2012, Nature.

[25]  John J. Irwin,et al.  ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..

[26]  M. Dubocovich,et al.  Phase-dependent treatment of delayed sleep phase syndrome with melatonin. , 2005, Sleep.

[27]  Christopher Browning,et al.  Pharmacological characterization of human recombinant melatonin mt1 and MT2 receptors , 2000, British journal of pharmacology.

[28]  J. Emens,et al.  The phase shift hypothesis for the circadian component of winter depression , 2007, Dialogues in clinical neuroscience.

[29]  P. Zee,et al.  Comparative effects of a melatonin agonist on the circadian system in mice and Syrian hamsters , 1997, Brain Research.

[30]  Dahlia R. Weiss,et al.  Selectivity Challenges in Docking Screens for GPCR Targets and Antitargets , 2018, Journal of medicinal chemistry.

[31]  M. Dubocovich Melatonin receptors: role on sleep and circadian rhythm regulation. , 2007, Sleep medicine.

[32]  J. Richardson,et al.  Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. , 1999, Journal of molecular biology.

[33]  C. M. Singer,et al.  The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light. , 1998, Chronobiology international.

[34]  J. Irwin,et al.  Docking Screens for Novel Ligands Conferring New Biology. , 2016, Journal of medicinal chemistry.

[35]  Xin Chen,et al.  Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65 , 2015, Nature.

[36]  N. Zisapel New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation , 2018, British journal of pharmacology.

[37]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[38]  Jing Liu,et al.  In silico design of novel probes for the atypical opioid receptor MRGPRX2 , 2016, Nature chemical biology.

[39]  C. Eastman,et al.  Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. , 2010, The Journal of clinical endocrinology and metabolism.

[40]  M. Dubocovich,et al.  Luzindole (N-0774): a novel melatonin receptor antagonist. , 1988, The Journal of pharmacology and experimental therapeutics.

[41]  M. Dubocovich,et al.  The antidepressant‐like effect of the melatonin receptor ligand luzindole in mice during forced swimming requires expression of MT2 but not MT1 melatonin receptors , 2005, Journal of pineal research.

[42]  M. Polymeropoulos,et al.  Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials , 2009, The Lancet.

[43]  M. Dubocovich,et al.  Selective MT2 melatonin receptor antagonists block melatonin‐mediated phase advances of circadian rhythms , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  Nathan Robertson,et al.  Article pubs.acs.org/jmc Identification of Novel Adenosine A 2A Receptor Antagonists by Virtual Screening , 2022 .

[45]  M. Caron,et al.  Regulation of beta-adrenergic receptors by guanyl-5'-yl imidodiphosphate and other purine nucleotides. , 1976, The Journal of biological chemistry.

[46]  Béla Noszál,et al.  Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. , 2008, Journal of medicinal chemistry.

[47]  Yvonne C. Martin,et al.  Application of Belief Theory to Similarity Data Fusion for Use in Analog Searching and Lead Hopping , 2008, J. Chem. Inf. Model..

[48]  M. Mor,et al.  Bivalent ligand approach on N-{2-[(3-methoxyphenyl)methylamino]ethyl}acetamide: synthesis, binding affinity and intrinsic activity for MT(1) and MT(2) melatonin receptors. , 2011, Bioorganic & medicinal chemistry.

[49]  Henry Lin,et al.  Structure-based discovery of opioid analgesics with reduced side effects , 2016, Nature.

[50]  Yurii S. Moroz,et al.  Ultra-large library docking for discovering new chemotypes , 2019, Nature.

[51]  Min-Sung Kim,et al.  Transient mammalian cell transfection with polyethylenimine (PEI). , 2013, Methods in enzymology.

[52]  M. Dubocovich,et al.  Effect of MT1 melatonin receptor deletion on melatonin‐mediated phase shift of circadian rhythms in the C57BL/6 mouse , 2005, Journal of pineal research.

[53]  Jonathan S. Mason,et al.  Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.

[54]  Arthur Christopoulos,et al.  A simple method for quantifying functional selectivity and agonist bias. , 2012, ACS chemical neuroscience.

[55]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[56]  J. Boutin,et al.  Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands. , 2003, Journal of medicinal chemistry.

[57]  M. Dubocovich,et al.  Functional Melatonin Receptors in Rat Ovaries at Various Stages of the Estrous Cycle , 2003, Journal of Pharmacology and Experimental Therapeutics.

[58]  M. Dubocovich,et al.  MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. , 2016, Annual review of pharmacology and toxicology.

[59]  T. Handel,et al.  What Do Structures Tell Us About Chemokine Receptor Function and Antagonism? , 2017, Annual review of biophysics.

[60]  M. Dubocovich,et al.  Circadian Periods of Sensitivity for Ramelteon on the onset of Running-wheel Activity and the Peak of Suprachiasmatic Nucleus Neuronal Firing Rhythms in C3H/HeN Mice , 2011, Chronobiology international.

[61]  M. Millan,et al.  Agomelatine, the first melatonergic antidepressant: discovery, characterization and development , 2010, Nature Reviews Drug Discovery.

[62]  Yurii S Moroz,et al.  Expanding Synthesizable Space of Disubstituted 1,2,4-Oxadiazoles. , 2016, ACS combinatorial science.

[63]  Harald Hübner,et al.  Structure-Guided Screening for Functionally Selective D2 Dopamine Receptor Ligands from a Virtual Chemical Library. , 2017, ACS chemical biology.